Everyone likes a great deal, and there’s no biotech stock I’d love to see go on sale more than Celgene (NASDAQ: CELG).Celgene’s blockbuster drugs, industry-leading profitability, and rock-solid balance sheet put it among the elite companies in the business. As a result, the company hasn’t given investors too many chances to buy its shares at a bargain price. But if […]
Here’s how to protect your profits in biotech: Trader
Susquehanna’s Stacey Gilbert thinks biotech could be due for a pullback. She lays out an options strategy to protect your biotech holdings.
It’s been a record-breaking run for biotech stocks, with the Nasdaq Biotech ETF, the IBB, up 18 percent this year alone and nearly 300 percent in the past five years. But […]
Biotech stocks have been on fire in 2015. In the Biotech & Pharmaceuticals sector of the Russell 2000 Growth Index, there are over sixty stocks up by more than 30% this year. More than thirty stocks are up greater than 50% while six have more than doubled.The iShares Biotechnology ETF (IBB) is already up more than 20% less than 3 […]
Akin Oyedele
Mar. 23, 2015, 2:21 PM
1,194
Biotech stocks are on fire.That’s given some analysts flashbacks of 2000, when tech valuations were red hot, but it didn’t end well because they crashed.Michael Batnick over at The Irrelevant Investor posted this chart Monday that compares the rally in tech stocks then to biotechs in recent years.He describes the biotech rally:”In the 168 weeks since […]
The multiyear run in major biotech stocks has not let up in 2015. Most of the large and mid-cap stocks in the industry are higher, but the smaller and lesser known names have also tracked them higher. In fact, several biotechs are up 200% or more so far in 2015.24/7 Wall St. ran a screen for the top five biotech […]
The multiyear run in major biotech stocks has not let up in 2015. Most of the large and mid-cap stocks in the industry are higher, but the smaller and lesser known names have also tracked them higher. In fact, several biotechs are up 200% or more so far in 2015.24/7 Wall St. ran a screen for the top five biotech […]
The stock has even more upside from where it was trading Friday, around $475 per share, Yaron Werber, senior biotech analyst at Citi Investment Research, told “Power Lunch.” As the Alzheimer’s drug likely will not reach the market for years, it is important to Biogen’s long-term prospects, he said.When looking at valuations, investors need to consider that low interest rates […]
The stock has even more upside from where it was trading Friday, around $475 per share, Yaron Werber, senior biotech analyst at Citi Investment Research, told “Power Lunch.” As the Alzheimer’s drug likely will not reach the market for years, it is important to Biogen’s long-term prospects, he said.When looking at valuations, investors need to consider that low interest rates […]
Related 13 Management Changes That Happened This Week8-K Filing Shows Bind Therapeutics Closes Offering Of StockRelated Morning Market LosersCerulean Announces Completion of Enrollment of a Phase 1b/2 Study of CRLX101 in Combination with Avastin® in Relapsed Renal Cell CarcinomaCerulean Pharma (CERU) Shares March Higher, Can It Continue? – Tale of the Tape(Zacks)In a recent report, analysts at JMP Securities discussed […]
Link:
Booming biotech stocks: REGN, CELG & more – Video
[…]
